Affordable Access

Publisher Website

Contemporary Prevalence of BRO β-Lactamases in Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (North America, 1997 to 2004)

Authors
Journal
Journal of Clinical Microbiology
0095-1137
Publisher
American Society for Microbiology
Publication Date
Volume
44
Issue
10
Identifiers
DOI: 10.1128/jcm.00456-06
Keywords
  • Bacteriology

Abstract

A total of 7,860 community-acquired Moraxella catarrhalis isolates (SENTRY Antimicrobial Surveillance Program, 1997 to 2004) were tested by broth microdilution methods, and 399 randomly selected strains from North American sites were tested for BRO-1 and BRO-2 by PCR methods. Several antimicrobials remained very active, including amoxicillin-clavulanate (MIC90s, ≤0.25 μg/ml), azithromycin (MIC90s, ≤0.12 μg/ml), ceftriaxone (MIC90s, 0.5 μg/ml), and levofloxacin (MIC90s, ≤0.03 to 0.06 μg/ml). The BRO-2 incidence rates by year were 3 to 4% overall (96 to 97% for BRO-1) and were the highest in Canada (7.9%), with the incidence in the United States being only 2.0%.

There are no comments yet on this publication. Be the first to share your thoughts.